Glycosylated CD147 reduces myocardial collagen cross‐linking in cardiac hypertrophy

The mechanism of transition from chronic pressure overload‐induced cardiac hypertrophy to heart failure is still unclear. Angiotensin II (Ang II) may be an important factor that mediates the transition in the end‐stage of cardiac hypertrophy. In the present study, Goldblatt two‐kidney one‐clip (2K1C) rat model was used to simulate Ang II‐induced hypertension. The elevated Ang II not only induced the concentric hypertrophy of left ventricle and cardiac fibrosis, but also increased the expression and glycosylation of CD147 in 2K1C rats. The left ventricular structure and function detected by echocardiogram showed a sign of the transition from cardiac hypertrophy to heart failure in 16 weeks of 2K1C rats. Ang II can activate N‐acetylglucosamine transferase V (GnT‐V), a key enzyme for CD147 glycosylation. Retinoic acid, an agonist of GnT‐V, further increased glycosylated CD147, and activated matrix metalloproteinase‐2/‐9 (MMP‐2 and MMP‐9) in the hypertrophied left ventricle of 2K1C rat. Meanwhile, collagen cross‐linking in the hypertrophied left ventricle significantly reduced in 2K1C rats. On the contrary, tunicamycin, an inhibitor of N‐glycan biosynthesis, inhibited glycosylation of CD147 and activity of MMP‐2 and MMP‐9, and then maintained a stable of collagen cross‐linking in the 2K1C rat hearts. The above results suggested that Ang II increased glycosylated CD147 which activated MMP‐2 and MMP‐9. Collagens were degraded by the activated MMPs and then reduced collagen cross‐linking. Finally, the hypertrophied left ventricle was progressively dilated in chronic pressure overload due to losing the limitation of collagen cross‐linking. Therefore, the compensated hypertrophy of left ventricle gradually transited to congestive heart failure.

[1]  A. Mathew,et al.  Polyphenol rich ethanolic extract from Boerhavia diffusa L. mitigates angiotensin II induced cardiac hypertrophy and fibrosis in rats. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Cheng-Zhi Wang,et al.  Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas , 2016, Medicine.

[3]  G. Fonarow,et al.  Epidemiology and aetiology of heart failure , 2016, Nature Reviews Cardiology.

[4]  D. Blumenthal,et al.  Caring for Coronary Artery Disease in China: Managing Modernization. , 2016, JAMA internal medicine.

[5]  R. Kurosawa,et al.  Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[6]  B. Toole,et al.  How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity , 2015, Bioscience reports.

[7]  S. R. Doren Matrix metalloproteinase interactions with collagen and elastin. , 2015 .

[8]  Y. Ye,et al.  Extracellular matrix metalloproteinase inducer (EMMPRIN) remodels the extracellular matrix through enhancing matrix metalloproteinases (MMPs) and inhibiting tissue inhibitors of MMPs expression in HPV-positive cervical cancer cells. , 2015, European journal of gynaecological oncology.

[9]  Zhi-Nan Chen,et al.  Importance of N-Glycosylation on CD147 for Its Biological Functions , 2014, International journal of molecular sciences.

[10]  Kathryn M. Spitler,et al.  Endoplasmic Reticulum Stress Contributes to Aortic Stiffening via Proapoptotic and Fibrotic Signaling Mechanisms , 2014, Hypertension.

[11]  D. Jelinek,et al.  CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells , 2013, Cell cycle.

[12]  S. Juan,et al.  Progressive changes of orexin system in a rat model of 6-hydroxydopamineinduced Parkinson’s disease , 2010 .

[13]  Long-Biao Cui,et al.  Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson's disease. , 2010, Neuroscience bulletin.

[14]  M. Teixeira,et al.  Role of the chemokines CCL3/MIP-1 alpha and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice. , 2009, Microvascular research.

[15]  Christine N. Koval,et al.  Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. , 2008, American journal of physiology. Heart and circulatory physiology.

[16]  P. Trackman Diverse biological functions of extracellular collagen processing enzymes , 2005, Journal of cellular biochemistry.

[17]  Merry L Lindsey,et al.  Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. , 2005, Cardiovascular research.

[18]  Zong-hou Shen,et al.  Modulation of the basal activity of N-acetylglucosaminyltransferase V by phosphatidylinositol-3-kinase/protein kinase B signaling pathway in human hepatocarcinoma cells , 2000, Glycoconjugate Journal.

[19]  T. Mela,et al.  Reduction in Myocardial Collagen Cross-Linking Parallels Left Ventricular Dilatation in Rat Models of Systolic Chamber Dysfunction , 2001, Circulation.

[20]  J. Ingwall,et al.  Regional changes in creatine kinase and myocyte size in hypertensive and nonhypertensive cardiac hypertrophy. , 1990, Circulation research.